Related Experiment Videos
Evaluation of diagnostic NOTCH3 immunostaining in CADASIL
Saskia A J Lesnik Oberstein1, Sjoerd G van Duinen, Rivka van den Boom
1Department of Clinical Genetics, K5-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. S.A.M.J.Lesnik_Oberstein@lumc.nl
Acta Neuropathologica
|May 21, 2003
Summary
NOTCH3 immunostaining aids in diagnosing Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) but is not definitive. Genetic testing remains essential for confirming CADASIL diagnosis.
Area of Science:
- Neurology
- Genetics
- Pathology
Background:
- Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a genetic disorder caused by NOTCH3 gene mutations.
- Diagnostic confirmation for CADASIL can be challenging and time-consuming.
- NOTCH3 immunostaining of skin biopsies is a recently developed diagnostic tool.
Purpose of the Study:
- To independently evaluate the diagnostic accuracy of NOTCH3 immunostaining for CADASIL.
- To assess the correlation between NOTCH3 immunostaining results and other CADASIL disease parameters.
Main Methods:
- NOTCH3 mutation status was determined in 62 individuals from 15 CADASIL families.
- Skin biopsy specimens underwent blind immunostaining and analysis by two independent observers.
- Immunostaining scores were correlated with clinical, genetic, and MRI data.
Main Results:
- Sensitivity ranged from 85.4% to 90.2%, and specificity from 95.2% to 100%, varying between observers.
- False-negative results were linked to specific NOTCH3 mutations; false-positives occurred in controls.
- No significant correlation was found between immunostaining scores and clinical or MRI findings.
Conclusions:
- NOTCH3 immunostaining is a supportive, not definitive, diagnostic test for CADASIL.
- Results must be interpreted alongside clinical and radiological data.
- DNA analysis is required for confirming positive results and for negative results in cases of high clinical suspicion.